Voltar
Artigo Produção Nacional Revisado por pares
BIBTEX RIS

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

2023; Lippincott Williams & Wilkins; Volume: 42; Issue: 2 Linguagem: Inglês

10.1200/jco.23.00980

ISSN

1527-7755

Autores

Daniel S.W. Tan, Enriqueta Felip, Gilberto de Castro, Benjamin Solomon, Alastair Greystoke, Byoung Chul Cho, Manuel Cobo, Tae Min Kim, Sandip Ganguly, Enric Carcereny, Luis Paz‐Ares, Jaafar Bennouna, Marina Chiara Garassino, Michael Schenker, Sang‐We Kim, Jan C. Brase, Denise Bury-Maynard, Vanessa Q. Passos, Stéphanie Deudon, Bharani Dharan, Yuanbo Song, Rafael Caparica, Bruce E. Johnson,

Tópico(s)

Lung Cancer Diagnosis and Treatment

Resumo

The addition of checkpoint inhibitors to first-line treatment has prolonged survival of patients with non-small-cell lung cancer (NSCLC), but prognosis remains poor, with new treatment options needed. Canakinumab, a human, monoclonal anti-interleukin (IL)-1β antibody, has potential to enhance the activity of PD-L1 inhibitors and chemotherapy (CT) by inhibiting protumor inflammation.

Referência(s)